Platelet transfusion strategy during stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares how platelets are given during a stem cell transplant to help prevent bleeding. It also watches for clotting risks, since platelets can affect both bleeding and clot formation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18+) having an autologous stem cell transplant (ASCT) for a blood cancer
- You can sign consent in writing before the transplant starts
- In the past year, you have not had a moderate or severe bleeding event (WHO grade 2–4)
- You have not had an unprovoked blood clot (like lung clot or brain clot)
- You are not currently needing strong blood thinners or anti-platelet medicines during the transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a medication called etamsylate can help prevent bleeding in patients getting a stem cell transplant. If your platelet count drops very low after transplant, this drug may reduce your risk of bleeding.
This trial tests how well platelet transfusions work for patients with blood cancers or bone marrow failure who have very low platelets and need a transfusion. It aims to see if the transfusions help control bleeding and improve outcomes.
This trial tests whether giving a medicine called rhTPO early can help prevent low blood platelets, a common side effect of the chemotherapy used to prepare your body for a stem cell transplant. The goal is to help you recover faster and reduce the need for platelet transfusions.
This trial tests whether giving back a patient's own platelets and red blood cells during heart surgery can reduce bleeding and the need for donor blood transfusions. It is for people having certain types of high-risk heart surgery with a heart-lung machine.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This study tests whether taking an antioxidant called NAC before a half-matched stem cell transplant helps platelets (the cells that help blood clot) recover faster in people with aplastic anemia. If you qualify, you may get NAC or a placebo, and the trial will see if it improves your recovery.
Hear when a new Hematologic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.